Breast Cancer

Sunil W. Dutta, MD, discussed hypofractionation in breast reconstruction and why clinical follow up remains a key "soft skill" in an AI-driven field.

Sunil Dutta, MD, discusses integrating FAST-Forward and PRIME II trial data to personalize breast cancer treatment and sequencing radiation with ADCs.

In this review, we highlight pivotal trials that have informed current practice and ongoing trials that may inform the therapeutic landscape in the coming years.

Fumiko Chino, MD, FASCO, discussed the psychological "free fall" patients may experience after completion of radiation therapy for breast cancer.

Surgical updates for invasive breast cancer from the NCCN Breast Cancer meeting revealed insights on neoadjuvant endocrine therapy and SLNB omission.

Parul Barry, MD, discusses advances such as ultrahypofractionated radiation and the growing role of AI in streamlining workflows for breast cancer care.

J. Isabelle Choi, MD, outlined evidence-based strategies for radiation dose escalation in locoregionally advanced breast cancer.

Ifeoma Dikeocha, PhD, discussed how metabolic restriction and fasting-mimicking diets can help optimize chemotherapy outcomes in breast cancer.

A PDUFA date in the second quarter of 2026 has been set for Dato-DXd in patients with unresectable or metastatic TNBC.

Soumen Das, MBBS, MS, FACS, discussed the BC-RADS-2 study, a community-integrated approach to standardizing breast cancer detection in low-resource settings through a structured clinical reporting and data system.

In the PATINA trial, adding palbociclib to maintenance therapy significantly improved progression-free survival in patients with HR+, HER2+ breast cancer.

Results of 9 patients with metastatic breast cancer dosed with Bria-IMT have shown sustained survival.

The FDA held a Type B meeting regarding the use of d3-T, a form of testosterone, and the risk of developing breast cancer in women.

Paxalisib combined with pembrolizumab and chemotherapy showed preliminary activity in patients with metastatic triple-negative breast cancer.

The BC-RADS-2 study aimed to address diagnostic delays and cancer care disparities of patients with breast cancer in low- and middle-income countries.

Soumen Das, MBBS, MS, FACS, discussed the BC-RADS-2 study and its potential to transform early breast cancer detection in low- and middle-income countries.

In the ASCENT-04/KEYNOTE-D19 trial, sacituzumab govitecan plus pembrolizumab significantly extended PFS in patients with first-line metastatic TNBC.

The FDA accepted the NDA for gedatolisib for HR+/HER2–, PIK3CA wild-type advanced breast cancer after it reduced the risk of disease progression or death.

The marketing authorization was based on results from the DESTINY-Breast09 trial assessing T-DXd/pertuzumab in first-line HER2+ metastatic breast cancer.

Investigators used the NCCN Distress Thermometer to identify psychological distress in Nigerian patients with breast cancer in a cross-sectional study.

Experts from VCU Massey Cancer Center discuss seamlessly integrating bioimpedance spectroscopy into standard workflows for lymphedema detection.

Researchers highlight the importance of geriatric assessments and patient-centered outcomes to manage unique physiological and functional challenges in older breast cancer survivors.

Previously, the phase 2 EVANGELINE trial assessed treatment with (Z)-endoxifen in this patient group.

Nurses preferred the FreedomEDGE infusion system compared with the manual push technique in a retrospective survey study.

VCU Massey Cancer Center is utilizing L-Dex bioimpedance spectroscopy to move toward a preventative model for lymphedema.